Understanding immune responses in autoimmune encephalitis and paraneoplastic neurological syndromes
Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes
This study is trying to find specific markers in the blood and spinal fluid of people with autoimmune encephalitis and paraneoplastic neurological syndromes to help improve diagnosis and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Lyon) |
| Trial ID | NCT05772611 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the immune responses in patients diagnosed with autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS). It focuses on identifying specific autoantibodies in serum and cerebrospinal fluid, which can serve as biomarkers for these conditions. By analyzing the presence of these autoantibodies, the study seeks to improve diagnostic accuracy and treatment outcomes through appropriate immunotherapy. The research will involve genetic and immunological testing to better understand the underlying mechanisms of these rare neuroimmune disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with neurological disorders who may or may not have specific autoantibodies present in their serum or cerebrospinal fluid.
Not a fit: Patients without available clinical data will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and improved treatment options for patients with autoimmune encephalitis and paraneoplastic neurological syndromes.
How similar studies have performed: While the study focuses on a specific characterization approach, similar studies have shown promise in identifying biomarkers for autoimmune conditions, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with neurological disorder * Patient with antibodies or not in sera or CSF Exclusion Criteria: \- No available clinical data
Where this trial is running
Lyon
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Jerome HONNORAT, MD
- Email: jerome.honnorat@chu-lyon.fr
- Phone: +33 4 72 35 78 06
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.